好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prevalence of Peripheral Nervous System Involvement in Adult Leukodystrophies
General Neurology
P2 - Poster Session 2 (11:45 AM-12:45 PM)
6-031
na

Leukodystrophies are genetic, neurodegenerative white matter diseases of the central nervous system (CNS) caused by mutations in various genes, presenting with heterogeneous clinical features and age of onset. It is well established that some leukodystrophies have peripheral nervous system (PNS) involvement, whether demyelinating, axonal or mixed in pathology. However, the prevalence of peripheral neuropathy in adult leukodystrophies is unknown. Early recognition of PNS involvement in these disorders is imperative to enable appropriate management and care of the symptoms. 

We performed a retrospective review of all adult subjects followed at our two institutions for white matter disease of genetic origin to select patients with evidence of PNS involvement as documented by nerve conduction studies (NCS) and/or electromyography (EMG)For these subjects we collected and analyzed data on sociodemographic status, family history, clinical characteristics, and disease course, nerve conduction studies (NCS), electromyography (EMG), MRI features and genetic testing results.

From our combined cohorts of 161 adult subjects followed for genetic white matter diseases, we identified 14 patients (8.7%) with documented PNS involvement. A definite genetic diagnosis was established in 5 subjects (3 with adult polyglucosan body disease, 1 with metachromatic leukodystrophy, 1 with POLR3-related disorder) while 9 subjects remained undiagnosed despite extensive genetic investigations. The demographic, clinical, radiological, and electrophysiological data will be presented. 

This is the first study conducted to assess the prevalence of peripheral neuropathy in adult patients with leukodystrophy. In our two independent cohorts, PNS involvement is rare, however, early recognition of the concurrence of CNS and PNS involvement is essential to plan appropriate management of the patients’ symptomatic care and is key as more treatment options are becoming available. 

Authors/Disclosures
Al-alya Alsabah, MD
PRESENTER
Dr. Alsabah has nothing to disclose.
No disclosure on file
Rami Massie, MD (McGill University) Dr. Massie has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Gowlingwlg. Dr. Massie has received personal compensation in the range of $500-$4,999 for serving as a Lecturer with Pfizer. Dr. Massie has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board with Argenx.
Bernard Brais, MD Dr. Brais has nothing to disclose.
Jennifer L. Orthmann Murphy, MD, PhD (Hospital of the University of Pennsylvania) Dr. Orthmann Murphy has received personal compensation in the range of $0-$499 for serving as a Consultant for Vigil Neuroscience. Dr. Orthmann Murphy has received personal compensation in the range of $0-$499 for serving as a Consultant for NovoGlia. The institution of Dr. Orthmann Murphy has received research support from Vigil Neurosciences. The institution of Dr. Orthmann Murphy has received research support from National MS Society. The institution of Dr. Orthmann Murphy has received research support from Fishman Family Foundation. The institution of Dr. Orthmann Murphy has received research support from Global Leukodystrophy Initiative Clinical Trial Network. The institution of Dr. Orthmann Murphy has received research support from NINDS. The institution of Dr. Orthmann Murphy has received research support from Montague Investigator Award. Dr. Orthmann Murphy has received personal compensation in the range of $500-$4,999 for serving as a Developing CME content on Neurogenetics with American Neurological Association. Dr. Orthmann Murphy has received personal compensation in the range of $500-$4,999 for serving as a Faculty, Honoraria with CMSC.
Roberta La Piana (McGill University) Roberta La Piana has received research support from Canadian Institute Health Research. Roberta La Piana has received research support from Ataxia Canada. Roberta La Piana has received research support from Spastic Paraplegia Foundation. Roberta La Piana has received research support from Fonds de Recherche en Santé du Quebec. Roberta La Piana has received research support from Roche Canada. Roberta La Piana has received research support from ARSACS Foundation.